Hyundai Bioscience Statistics

Total Valuation

Hyundai Bioscience has a market cap or net worth of KRW 545.92 billion. The enterprise value is 563.22 billion.

Market Cap	545.92B
Enterprise Value	563.22B

Important Dates

The next estimated earnings date is Monday, March 17, 2025.

Earnings Date	Mar 17, 2025
Ex-Dividend Date	n/a

Share Statistics

Hyundai Bioscience has 39.82 million shares outstanding. The number of shares has increased by 0.18% in one year.

Current Share Class	n/a
Shares Outstanding	39.82M
Shares Change (YoY)	+0.18%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.80%
Owned by Institutions (%)	6.82%
Float	34.66M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	34.51
PB Ratio	12.48
P/TBV Ratio	51.65
P/FCF Ratio	109.72
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-53.95
EV / Sales	35.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	113.20

Financial Position

The company has a current ratio of 0.34, with a Debt / Equity ratio of 0.58.

Current Ratio	0.34
Quick Ratio	0.32
Debt / Equity	0.58
Debt / EBITDA	33.74
Debt / FCF	5.09
Interest Coverage	0.06

Financial Efficiency

Return on equity (ROE) is -21.50% and return on invested capital (ROIC) is 0.08%.

Return on Equity (ROE)	-21.50%
Return on Assets (ROA)	0.07%
Return on Capital (ROIC)	0.08%
Revenue Per Employee	292.93M
Profits Per Employee	-193.33M
Employee Count	54
Asset Turnover	0.24
Inventory Turnover	2.82

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -46.65% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-46.65%
50-Day Moving Average	15,706.40
200-Day Moving Average	18,598.15
Relative Strength Index (RSI)	41.81
Average Volume (20 Days)	253,541

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hyundai Bioscience had revenue of KRW 15.82 billion and -10.44 billion in losses. Loss per share was -262.85.

Revenue	15.82B
Gross Profit	12.01B
Operating Income	78.78M
Pretax Income	-10.44B
Net Income	-10.44B
EBITDA	751.35M
EBIT	78.78M
Loss Per Share	-262.85

Full Income Statement

Balance Sheet

The company has 8.06 billion in cash and 25.35 billion in debt, giving a net cash position of -17.29 billion or -434.27 per share.

Cash & Cash Equivalents	8.06B
Total Debt	25.35B
Net Cash	-17.29B
Net Cash Per Share	-434.27
Equity (Book Value)	43.74B
Book Value Per Share	1,098.47
Working Capital	-17.36B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 5.06 billion and capital expenditures -84.95 million, giving a free cash flow of 4.98 billion.

Operating Cash Flow	5.06B
Capital Expenditures	-84.95M
Free Cash Flow	4.98B
FCF Per Share	124.95

Full Cash Flow Statement

Margins

Gross margin is 75.89%, with operating and profit margins of 0.50% and -66.00%.

Gross Margin	75.89%
Operating Margin	0.50%
Pretax Margin	-65.99%
Profit Margin	-66.00%
EBITDA Margin	4.75%
EBIT Margin	0.50%
FCF Margin	31.45%

Dividends & Yields

Hyundai Bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.18%
Shareholder Yield	-0.18%
Earnings Yield	-1.92%
FCF Yield	0.91%

Stock Splits

The last stock split was on December 16, 2011. It was a reverse split with a ratio of 0.1.

Last Split Date	Dec 16, 2011
Split Type	Reverse
Split Ratio	0.1

Scores

Hyundai Bioscience has an Altman Z-Score of 19.69.

Altman Z-Score	19.69
Piotroski F-Score	n/a